2022 Universal Registration Document

Chapter 5 : 2022 Consolidated Financial Statements

5.5. Share subscription or purchase options – Free shares
Accounting principles

In accordance with the requirements of IFRS 2 “Share-based Payment”, the value of options or free shares granted as calculated at the grant date is expensed in the income statement over the vesting period, which is generally five years for purchase options and four years for free shares.

The fair value of free shares corresponds to the value of the share at the grant date, less dividends expected to be paid during the vesting period.

The impact of IFRS 2 on profit for the period is booked on the Selling, general and administrative expenses item of the income statement at Group level, and is not allocated to the Divisions or geographic zones.

a) Share subscription or purchase options

There is no option plans in force at 31 December 2022.

Data concerning all share option plans during financial years 2022, 2021 and 2020 are set out below:

  31.12.2022 31.12.2021 31.12.2020
  Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price
Number of options not exercised at beginning of period   57,397 €83.19 524,193 €81.91
Options granted        
Options exercised     -52,397 €83.19 -465,796 €81.76
Options expired     -5,000   -1,000  
Number of options not exercised at end of period     57,397 €83.19
Of which:            
number of exercisable options at end of period         57,397 €83.19
expired options at end of period          
Weighted average share price       €364.74   €273.24
b) Free shares

The table below summarises the data on free share plans vesting after 1 January 2020.

Grant date        
Stock subscription plans Vesting date Number of shares granted Number of shares issued/allotted Number of shares not finally vested
20.04.2016

20.04.2016

 

21.04.2020

20.04.2016

 

906,100

20.04.2016

 

835,725

20.04.2016

 

20.04.2017

20.04.2017

 

21.04.2021

20.04.2017

 

906,000

20.04.2017

 

742,276

20.04.2017

 

17.04.2018

17.04.2018

 

18.04.2022

17.04.2018

 

931,000

17.04.2018

 

868,575

17.04.2018

 

18.04.2019

18.04.2019

 

19.04.2023

18.04.2019

 

843,075

18.04.2019

 

450

18.04.2019

 

801,400

14.10.2020

14.10.2020

 

15.10.2024

14.10.2020

 

713,660

14.10.2020

 

385

14.10.2020

 

691,150

07.10.2021

07.10.2021

 

08.10.2025

07.10.2021

 

588,750

07.10.2021

 

105

07.10.2021

 

578,325

13.10.2022

13.10.2022

 

14.10.2026

13.10.2022

 

700,000

13.10.2022

 

13.10.2022

 

700,000

For the conditional grant of shares, the plan provides for a four-year vesting period after which vesting is effective and final, subject to meeting the conditions of the plan.

The performance conditions apply to the 7 October 2021,14 October 2020 and 18 April 2019 plans:

  • for 50% of shares granted, the growth in comparable Cosmetics sales in relation to growth in net sales for a panel of competitors:
    • 2022, 2023 and 2024 financial years under the 2021 plan,
    • 2021, 2022 and 2023 financial years under the 2020 plan,
    • 2020, 2021 and 2022 financial years under the 2019 plan;
  • for 50% of shares granted, the increase over the same period in the Group’s consolidated operating profit for the7 October 2021, 14 October 2020 and 18 April 2019 plans.

The calculation will be based on the mean of the performance in the:

  • 2022, 2023 and 2024 financial years under the 2021 plan;
  • 2021, 2022 and 2023 financial years under the 2020 plan;
  • 2020, 2021 and 2022 financial years under the 2019 plan;

and will use a predefined allocation scale based on the performance percentage achieved. No performance condition applies below a block of 200 shares.

For the 13 October 2022 plan, the performance conditions comprise the following:

  • 80% based on financial performance criteria, split evenly between:
    • growth – compared with that of a panel of competitors –in comparable cosmetics sales for financial years 2023,2024 and 2025,
    • the increase over the same period in the Group’s consolidated operating profit. The calculation will be made on the basis of the arithmetic average of the performances for 2023, 2024 and 2025,